Cargando…

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer

BACKGROUND: To determine the 5-year outcome after high-dose-rate brachytherapy (HDR-BT) as a monotherapy. METHODS: Between 10/2003 and 06/2006, 36 patients with low (28) and intermediate (8) risk prostate cancer were treated by HDR-BT monotherapy. All patients received one implant and 4 fractions of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghadjar, Pirus, Oesch, Sebastian L, Rentsch, Cyrill A, Isaak, Bernhard, Cihoric, Nikola, Manser, Peter, Thalmann, George N, Aebersold, Daniel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4046044/ https://www.ncbi.nlm.nih.gov/pubmed/24885327 http://dx.doi.org/10.1186/1748-717X-9-122

Ejemplares similares

Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking
por: Ghadjar, Pirus, et al.
Publicado: (2008)

Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy
por: Cihoric, Nikola, et al.
Publicado: (2012)

Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database
por: Cihoric, Nikola, et al.
Publicado: (2016)

Prevention of radiochemotherapy-induced toxicity with amifostine in patients with malignant orbital tumors involving the lacrimal gland: a pilot study
por: Goldblum, David, et al.
Publicado: (2008)

Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
por: Cihoric, Nikola, et al.
Publicado: (2018)

Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma
por: Geretschläger, Andreas, et al.
Publicado: (2012)

Postoperative Radiotherapy after Radical Prostatectomy: Indications and Open Questions
por: Ghadjar, Pirus, et al.
Publicado: (2012)

The emerging role of high-dose-rate (HDR) brachytherapy as monotherapy for prostate cancer
por: Yoshioka, Yasuo, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective
por: Yoshioka, Yasuo, et al.
Publicado: (2014)

Quality of life after high-dose-rate brachytherapy monotherapy for prostate cancer
por: Contreras, Jessika A., et al.
Publicado: (2015)

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer
por: Barnes, Justin, et al.
Publicado: (2019)

Current status and perspectives of interventional clinical trials for glioblastoma – analysis of ClinicalTrials.gov
por: Cihoric, Nikola, et al.
Publicado: (2017)

High-dose-rate brachytherapy delivered in two fractions as monotherapy for low-risk prostate cancer
por: Cendales, Ricardo, et al.
Publicado: (2015)

A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
por: Hathout, Lara, et al.
Publicado: (2019)

Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
por: Galego, Pedro, et al.
Publicado: (2015)

Single fraction high-dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: toxicities and early outcomes from a single institutional experience
por: Barnes, Justin M., et al.
Publicado: (2019)

A Report on the Clinical Outcome after High-Dose Rate (HDR) Brachytherapy as Monotherapy in Early Prostate Cancer
por: Potharaju, Mahadev, et al.
Publicado: (2015)

High-dose-rate fractionated brachytherapy monotherapy for localized prostate cancer: a systematic review and meta-analysis
por: Anderson, Eric M., et al.
Publicado: (2021)

Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer
por: Cihoric, Nikola, et al.
Publicado: (2015)

A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
por: Guirado, Damián, et al.
Publicado: (2020)

Treatment strategies to prevent and reduce gynecomastia and/or breast pain caused by antiandrogen therapy for prostate cancer: Statement from the DEGRO working group prostate cancer
por: Ghadjar, Pirus, et al.
Publicado: (2020)

Role of Dose Intensification for Salvage Radiation Therapy after Radical Prostatectomy
por: Beck, Marcus, et al.
Publicado: (2016)

High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses – 14 years of single-centre experience
por: Soatti, Carlo Pietro, et al.
Publicado: (2020)

Dose-escalated radiotherapy for unresectable or locally recurrent pancreatic cancer: Dose volume analysis, toxicity and outcome of 28 consecutive patients
por: Zschaeck, Sebastian, et al.
Publicado: (2017)

Definitive intensity modulated radiotherapy in locally advanced hypopharygeal and laryngeal squamous cell carcinoma: mature treatment results and patterns of locoregional failure
por: Geretschläger, Andreas, et al.
Publicado: (2015)

Intermediate-term outcome after PSMA-PET guided high-dose radiotherapy of recurrent high-risk prostate cancer patients
por: Zschaeck, Sebastian, et al.
Publicado: (2017)

Radiotherapy in nodal oligorecurrent prostate cancer
por: Pinkawa, Michael, et al.
Publicado: (2021)

High dose rate brachytherapy as monotherapy for localised prostate cancer: a hypofractionated two-implant approach in 351 consecutive patients
por: Tselis, Nikolaos, et al.
Publicado: (2013)

High-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancer: long-term experience of Swedish single-center
por: Johansson, Bengt, et al.
Publicado: (2021)

Predicting toxicity caused by high-dose-rate brachytherapy single boost for prostate cancer
por: Olsén, Johan Staby, et al.
Publicado: (2022)

Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial
por: Müller, Arndt-Christian, et al.
Publicado: (2015)

Acute and late toxicities in localized prostate cancer patients treated with low-dose (125)I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy)
por: Mukai, Yuki, et al.
Publicado: (2018)

The potential of low-dose-rate brachytherapy with iodine-125 in the treatment of local recurrences of prostate cancer after primary high-dose-rate monotherapy
por: Burchardt, Wojciech M., et al.
Publicado: (2023)

Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer
por: Wolf, Frank, et al.
Publicado: (2020)

Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation
por: Bodis, Stephan, et al.
Publicado: (2022)

Tailored total lymphoid irradiation in heart transplant patients: 10-years experience of one center
por: Ghadjar, Pirus, et al.
Publicado: (2010)

Low dose rate prostate brachytherapy
por: Stish, Bradley J., et al.
Publicado: (2018)

High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2018)

Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer – Brachytherapy enhanced late GU toxicity especially in elderly
por: Yamazaki, Hideya, et al.
Publicado: (2020)

Risk adapted dose-intensified postoperative radiation therapy in prostate cancer patients using a simultaneous integrated boost technique applied with helical Tomotherapy
por: Beck, Marcus, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9cmen57sa6cadobe74f6658u7m